Galapagos NV (GLPGa)

52.40
-0.87(-1.62%)
  • Volume:
    28,155
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    52.18 - 52.90

GLPGa Overview

Prev. Close
53.27
Day's Range
52.18-52.9
Revenue
-
Open
52.42
52 wk Range
41.6-66.82
EPS
-
Volume
28,155
Market Cap
3.47B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
73,980
P/E Ratio
-
Beta
-
1-Year Change
-13.19%
Shares Outstanding
65,648,221
Next Earnings Date
03 Aug 2022
What is your sentiment on Galapagos?
or
Market is currently closed. Voting is open during market hours.

Galapagos NV News

Galapagos NV Company Profile

Galapagos NV Company Profile

Employees
1319

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellSellStrong Sell
Technical IndicatorsStrong SellStrong BuyNeutralStrong SellStrong Sell
SummaryStrong SellNeutralNeutralStrong SellStrong Sell